OVID
Ovid Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.80
+0.72%Aug 13, 2026, 12:30 UTC
Ovid Therapeutics Inc. reported its financial results for the second quarter ended June 30, 2026.
Source:Jul 8, 2026, 11:53 UTC
Ovid Therapeutics appointed Kevin Norrett as Chief Business Officer and promoted its CFO and Chief Strategy Officer.
Source:Jul 8, 2026, 00:00 UTC
Jeffrey Rona departed as Chief Business and Financial Officer of Ovid Therapeutics Inc. effective July 6, 2026, and Charles Carter was promoted to Chief Financial Officer, principal financial officer, principal accounting officer and secretary, effective the same date.